Mediobanca May Delay Vote on Banca Generali Bid, Repubblica Says

By and Sonia Sirletti
Save
Mediobanca called a board meeting on Sunday to decide whether to postpone an investor meeting to endorse its plan to takeover Banca Generali SpA, La Repubblica reports, without mentioning where it obtained the information.
According to the newspaper, a potential delay of the shareholder meeting, scheduled for Monday, would be justified as some of Mediobanca's shareholders, such as billionaire Francesco Gaetano Caltagirone, asked earlier this month for a postponement due to lack of sufficient information to make a decision.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

37 minutes ago

• Yahoo

Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an 'Overweight' rating on the stock with a $145 price target. The bullish stance follows positive discussions with a European specialist on the company's VYKAT XR medication for Prader-Willi syndrome (PWS). A scientist in a laboratory examining a microscope in the pursuit of cell therapy discoveries. Piper Sandler consulted a UK-based pediatric endocrinologist to understand the drug better. The specialist indicated she would prescribe the drug as medication for Prader-Willi syndrome (PWS) to all eligible patients upon approval. Soleno Therapeutics' edge with the drug stems from the fact that other PWS treatments are in the early stages of development. Piper Sandler believes VYKAT XT represents significant potential as the first approved treatment specifically addressing PWS, a condition. The biotech company plans to file a Marketing Authorization Application for VYKAT XR in the second quarter. It's also pursuing regulatory approval in Europe as it plans to fill with the European Medicines agency. Following regulatory approvals, Soleno Therapeutics Palms will launch the drug in the first quarter of 2026. Soleno Therapeutics is a biopharmaceutical company that develops and commercializes novel treatments for rare diseases. Their lead product, diazoxide choline extended-release tablets (DCCR), is being developed for Prader-Willi syndrome (PWS), specifically to address hyperphagia (excessive hunger). While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bloomberg

an hour ago

• Bloomberg

Plunging UK Retail Sales Deepen Concern About Broader Slowdown

A dramatic drop in UK retail sales is raising fresh questions about the sustainability of Britain's recent growth spurt and Prime Minister Keir Starmer's plans to use it to restore controversial benefit cuts. The volume of goods sold online and in shops dropped 2.7% in May, the Office for National Statistics said on Friday. Not only was that the sharpest decline since December 2023, it was enough to wipe out the combined gains over the previous four months of the year. Economists had expected retail sales to fall only 0.5% last month.

Yahoo

2 hours ago

• Yahoo

UBS Keeps Buy Rating on Cheniere Energy (LNG)

Cheniere Energy, Inc. (NYSE:LNG) is one of the 10 Best Oil and Gas Stocks to Buy Now. On June 16, UBS maintained its 'Buy' rating on Cheniere Energy, Inc. (NYSE:LNG) with a $277 price target. The firm highlighted the company's plans to expand and its shareholder return strategy. UBS pointed out Cheniere Energy, Inc.'s (NYSE:LNG) SPL expansion project, which will add a total production capacity of about 20 million tonnes per annum (mtpa) of liquefied natural gas (LNG). The company aims to achieve this through three liquefaction trains, each with a capacity of around 6 mtpa. The project also includes debottlenecking opportunities. UBS estimates the total cost of this project will be between $15 billion and $18 billion. Close-up of a liquefied natural gas terminal expelling plumes of smoke. Cheniere Energy, Inc. (NYSE:LNG) still has about $3.5 billion left under its share buyback program. The company aims to repurchase $4 billion worth of shares by 2027. UBS analysts highlighted that the management team expects to complete the authorized buybacks ahead of schedule. Cheniere Energy, Inc. (NYSE:LNG) is an American energy company primarily engaged in LNG-related businesses. It is the leading producer and exporter of LNG in the US. While we acknowledge the potential of LNG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data